Publications by authors named "J Lloreta"
Article Synopsis
- Immune checkpoint inhibitors (ICI) have transformed cancer treatment, allowing complete remissions in advanced stages, but only a small number of patients respond.
- Researchers analyzed DNA and RNA data from 27 advanced urothelial carcinoma patients treated with anti-PD-(L)1 antibodies, focusing on factors like tumor mutational burden (TMB) and immune cell markers.
- The study found a strong association between response to treatment and clonal mutations, suggesting that cancers with more clonal cells may respond better, and highlighted high immune cell marker levels as a potential predictive biomarker for effective treatment.
Article Synopsis
- The study aims to identify new genetic variants that increase the risk of bladder cancer using data from 32 studies involving 13,790 patients and 343,502 control subjects of European descent.
- Researchers discovered multiple novel susceptibility loci and enhanced signals in known regions, achieving a total of 24 significant markers linked to bladder cancer risk.
- The findings indicate that the risk is further influenced by factors such as sex and smoking status, with a polygenic risk score showing a significant difference in lifetime risk for bladder cancer based on genetic predisposition.
Colony-stimulating factor 1 receptor (CSF1R) inhibitors represent a new class of immune-modulatory drugs, mostly investigated in clinical trials in different malignant neoplasms. Four patients, diagnosed with recurrent or advanced malignant neoplasm and treated with a combination of anti-programmed death ligand 1 and anti-CSF1R monoclonal antibodies, developed an asymptomatic cutaneous eruption characterized by an ill-defined pseudoedematous to waxy diffuse infiltration with a reticular cobblestone-like pattern. Histopathological examination revealed diffuse mucin deposition involving the superficial and mid-dermis with fragmented and scattered elastic fibers.
View Article and Find Full Text PDFNo consensus currently exist on the optimal treatment of patients with high-risk nonmuscle invasive (HGT1) micropapillary variant of bladder cancer (MPBC). Transcripsome analysis may allow stratification of MPBC-HGT1 enabling prediction of recurrence and guide therapeutic management for individual patients. Whole transcriptome RNA-Sequencing of tumors from 23 patients with MPBC-HGT1 and 64 conventional urothelial carcinomas (cUC) (reference set) was performed.
View Article and Find Full Text PDFBackground: The International Agency for Research on Cancer (IARC) classifies diesel engine exhaust as carcinogenic to humans based on sufficient evidence for lung cancer. IARC noted, however, an increased risk of bladder cancer (based on limited evidence).
Objective: To evaluate the association between quantitative, lifetime occupational diesel exhaust exposure and risk of urothelial cell carcinoma of the bladder (UBC) overall and according to pathological subtypes.